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Cav1.3 L-type Ca2+-channel function is regulated by a C-terminal automodulatory
domain (CTM). It affects channel binding of calmodulin and thereby tunes channel
activity by interfering with Ca2+- and voltage-dependent gating. Alternative splicing
generates short C-terminal channel variants lacking the CTM resulting in enhanced
Ca2+-dependent inactivation and stronger voltage-sensitivity upon heterologous
expression. However, the role of this modulatory domain for channel function in its native
environment is unkown. To determine its functional significance in vivo, we interrupted
the CTM with a hemagglutinin tag in mutant mice (Cav1.3DCRDHA/HA). Using these
mice we provide biochemical evidence for the existence of long (CTM-containing)
and short (CTM-deficient) Cav1.3 α1-subunits in brain. The long (HA-labeled) Cav1.3
isoform was present in all ribbon synapses of cochlear inner hair cells. CTM-elimination
impaired Ca2+-dependent inactivation of Ca2+-currents in hair cells but increased it in
chromaffin cells, resulting in hyperpolarized resting potentials and reduced pacemaking.
CTM disruption did not affect hearing thresholds. We show that the modulatory function
of the CTM is affected by its native environment in different cells and thus occurs in
a cell-type specific manner in vivo. It stabilizes gating properties of Cav1.3 channels
required for normal electrical excitability.
Keywords: calcium channels, channel gating, hearing, hair cell, alternative splicing, chromaffin cells
Introduction
Ca2+ entering cells through voltage-gated L-type Ca2+-channels (LTCCs, Cav1) serves as
important second messenger for many diﬀerent cellular events. It is required for normal muscle
contraction, hormone secretion, sensory cell signaling, neuronal excitability and plasticity (Simms
and Zamponi, 2014; Striessnig et al., 2014 for reviews). Four α1-subunits (Cav1.1–Cav1.4) form
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diﬀerent LTCC isoforms. Cav1.1 (excitation-contraction
coupling in skeletal muscle) and Cav1.4 (retinal signaling) serve
more restricted functions, whereas Cav1.2 and Cav1.3 are widely
expressed in the mammalian organism and often co-exist in
the same cell (Berger and Bartsch, 2014; Striessnig et al., 2014).
Diﬀerent biophysical properties and protein interactions allow
them to support distinct physiological processes (Shaw and
Colecraft, 2013; Simms and Zamponi, 2014; Striessnig et al.,
2014). In the brain, Cav1.2 and Cav1.3 are located at postsynaptic
sites where their Ca2+ signals couple synaptic activity to gene
transcription (Ma et al., 2013) and thus play a key role in synaptic
plasticity, diﬀerent types of memory and neuronal development
(Striessnig and Koschak, 2008; Simms and Zamponi, 2014;
Striessnig et al., 2014). Cav1.3 also stabilizes upstate potentials,
regulates spine density and synaptic reﬁnement (Simms and
Zamponi, 2014; Striessnig et al., 2014). In cochlear inner
hair cells (IHCs), Cav1.3-mediated Ca2+ inﬂux drives sound-
induced glutamate release and is essential for hearing. Cav1.3
supports normal sinoatrial node pacemaking. Cav1.3-deﬁcient
(Cav1.3−/−) mice are deaf and show sinoatrial node dysfunction
(Simms and Zamponi, 2014; Striessnig et al., 2014). The low
activation threshold of Cav1.3 channels (Lipscombe et al., 2004;
Lieb et al., 2014; Striessnig et al., 2014) enables them to contribute
to pacemaking also in adrenal chromaﬃn cells (Marcantoni et al.,
2010; Vandael et al., 2012). Moreover, Cav1.3 provides Ca2+ for
aldosterone production (Azizan et al., 2013; Scholl et al., 2013).
Human diseases resulting from aberrant Cav1.3 LTCC
function (CACNA1D gene) have been described. Cav1.3-
deﬁciency replicates the phenotype observed in mice with
sinoatrial node dysfunction and deafness (SANDD, OMIM
#614896; Baig et al., 2011). In contrast, CACNA1D mutations
that alter Cav1.3 gating properties leading to enhanced
Ca2+ currents aﬀect also other tissues, including the brain.
Mutations enhancing Cav1.3 activity were discovered in
patients with a severe congenital multiorgan syndrome with
primary aldosteronism, seizures and neurologic abnormalities
including global developmental delay and intellectual disability
(PASNA, OMIM #615474) (Azizan et al., 2013; Scholl et al.,
2013). Moreover, we have recently reported that similar
de novo CANCNA1D mutations strongly contribute to
disease risk in two patients with autism and intellectual
impairment (Pinggera et al., 2015). These ﬁndings illustrate
the importance for tight control of Cav1.3 activity, and that
dysregulation of Cav1.3 predisposes to neuropsychiatric and
neurodevelopmental disorders (De Rubeis et al., 2014; Striessnig
et al., 2015).
Considering the essential physiological roles of LTCCs,
an important question is how channel function is adjusted
in vivo to prevent inappropriate Ca2+ signals. One well-
characterized autoinhibitory mechanism inherent to most
VGCCs is Ca2+-induced inactivation (CDI), which limits
Ca2+ inﬂux in response to Ca2+ entry and toxic intracellular
Ca2+ accumulation (for recent review Ben-Johny and Yue,
2014). Calmodulin (CaM) binding to the proximal C-terminus
of the pore-forming α1-subunit mediates the Ca2+-induced
conformational changes promoting CDI (Ben-Johny and Yue,
2014). However, CDI itself is further subject to ﬁne-tuning. In the
cochlea CaM-mediated CDI is strongly suppressed by competing
Ca2+-binding proteins (CaBPs) that do not support CDI (Cui
et al., 2007; Schrauwen et al., 2012; Ben-Johny and Yue, 2014).
In the case of Cav1.3, two other mechanisms have been identiﬁed
that can reduce CaM aﬃnity for the C-terminus and thus CDI:
RNA-editing (Huang et al., 2012; Bazzazi et al., 2013) and a
C-terminal automodulatory domain (CTM; Singh et al., 2008;
Tan et al., 2011).
This CTM forms by interaction of two putative α-helical
domains – a proximal and a distal C-terminal regulatory domain
(PCRD and DCRD, respectively; Singh et al., 2008). In brain
and other tissues, alternative splicing of Cav1.3 α1 generates
C-terminally truncated Cav1.3 α1 mRNA species that lack a
functional CTM, i.e., C-terminally long and short Cav1.3 α1
isoforms (Bock et al., 2011; Tan et al., 2011). Biochemical
and functional studies in HEK-293 cells revealed that the
CTM forms a module that inhibits CDI by competing with
CaM binding to its well characterized interaction sites within
the proximal C-terminal tail (Ben-Johny and Yue, 2014) and
that it also decreases channel open probability and reduces
the voltage-sensitivity of pore opening (Singh et al., 2008;
Bock et al., 2011; Lieb et al., 2014). Therefore alternative
splicing aﬀects Cav1.3 channel activity. Despite these detailed
studies in recombinant systems the role of this modulatory
mechanism for in vivo channel function is completely unknown.
Although two size forms of Cav1.3 α1 have been detected
in rodent brain (Hell et al., 1993) unequivocal proof for
the existence of C-terminally short forms without functional
CTM is lacking. It is also unclear whether these diﬀerent
size forms arise from alternative splicing or from C-terminal
proteolytic processing as reported for Cav1.2 (Gomez-Ospina
et al., 2006; Hulme et al., 2006). Although functional studies
with recombinant channels predict enhanced CDI, higher open
probability, and channel activation at lower voltages for short
splice variants in vitro, the physiological signiﬁcance of this
splicing-dependent regulation of Cav1.3 channel gating in vivo
is still unclear. It is also diﬃcult to predict how the native
cellular environment aﬀects Cav1.3 regulation by the CTM. For
example, it is unclear if the CTM also aﬀects channel function
in cells in which CaBPs strongly compete with CaM and largely
remove CDI.
To address this question we generated a novel mouse model in
which we disrupted CTM function in the long Cav1.3 C-terminus
by replacing part of the DCRD domain in exon 49 of the
CACNA1D gene by homologous recombination with an HA-
epitope (Cav1.3DCRDHA/HA mice). This allowed us to directly
immunolabel CTM-containing Cav1.3 variants and to quantify
the functional consequences of disrupted CTM function in vitro
and in vivo. We provide biochemical evidence for the existence of
long and short Cav1.3 α1-subunit polypeptides with and without
CTM, identify the long variants as intrinsic constituent of all
ribbon synapses in IHCs and discovered an unexpected, cell-
speciﬁc regulation of Cav1.3 CDI in mouse chromaﬃn cells
(MCCs) and IHCs. We further show that the CTM controls
resting membrane potential and spontaneous pacemaking in
MCCs. Our data reveal the CTM as an important regulatory
mechanism required for normal Ca2+ signaling.
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Materials and Methods
All procedures with animals were approved by the national
ethical committee on animal care and use (Austrian
Bundesministerium für Wissenschaft und Forschung) and
are in compliance with international laws and policies.
Cloning of cDNA Constructs
mCav1.3L-HA: mCav1.3L–HA was generated by replacing amino
acids 2080-2083 (DEME) in the DCRD region of the mouse
Cav1.3 α1 subunit cDNA (Klugbauer et al., 2002; Genbank
accession NM_001083616) by an HA-antibody tag. Correct
integration of the HA-tag was veriﬁed by sequencing (Euroﬁns
MWGOperon).
Generation of Cav1.3DCRDHA/HA Mice
Bac clone bMQ427c09 (Adams et al., 2005), which includes
exon 8–49 of the mouse CACNA1D gene was digested with
BamHI, and a 6399 bp fragment containing exon 48 and 49
(position 30045040-30038642, Ref: NC_000080.6) was ligated
with BamHI-digested and dephosphorylated pBluescript II SK
(−) (pBS). The resulting subclone (BampBS) was digested with
NaeI and HindIII and religated after blunting with T4 DNA
Polymerase (Fermentas) to exclude a ClaI restriction site. For
extension of the genomic region, a PCR product with an
additional artiﬁcial NotI∗ restriction site was ampliﬁed (primer:
fwd: 5′-ATA ATA GCG GCC GCT GAG CTT ATG TCC
CCA ATT AG-3′; rev, 5′-GCT GGG GTG CAC TAC CCA
CT-3′, template bMQ427c09, position 30037757 – 30039650
of NC_000080.6), subcloned into pJET1.2 (Thermo Scientiﬁc,
Germany) and transferred into BampBS via BstEII – NotI
(1987 bp) fragment exchange, yielding BamExtpBS. A 279 bp
ClaI-BsmBI fragment resembling position 30042386 – 30042050
in NC_000080.6 was synthesized (Euroﬁns MWG Operon). The
synthetic fragment contained an HA-tag to replace amino acid
residues DEME (single amino acid letter code; 30042270 –
30042259 in NC_000080.6) in the DCRD domain (Singh et al.,
2008) and artiﬁcial restriction sites XbaI∗ and SalI∗ after
the stop codon. The synthetic fragment was demethylated
by transformation of Dam− and Dcm− Escherichia coli GM
2163 (Thermo Scientiﬁc, Germany) and incorporated into
BamExtpBS via ClaI – BsmBI fragment exchange, yielding
BamExtSynpBS. The neomycin resistance gene was removed
from pL452 (ncifrederick.cancer.gov; Liu et al., 2003) by XhoI
digest and ligated with the SalI – digested and dephosphorylated
BamExtSynpBS construct, yielding BamExtSynNeopBS. The
negative selection marker HSV-TK was ampliﬁed by PCR
(primers: fwd, 5′-CTC GAG GCT AGA ACT AGT GG-3′; rev,
5′-GGT ATC GAC AGA GTG CCA G-3′, template: pL253
(ncifrederick.cancer.gov; Liu et al., 2003) and incorporated into
the SmaI digested BamExtSynNeopBS construct via blunt end
ligation. The construct sequence was veriﬁed by Euroﬁns MWG
operon. Mutant mice were generated using standard procedures
for homologous recombination in ES-cells (R1 derived from
129/Sv). Clones with correct targeting were identiﬁed by PCR
with the longAmp Taq DNA Polymerase (New England Biolabs).
Primers for short homologous arm: FH1, 5′-GTC CTT CCA
TCG CCT GCC CTG CCT C-3′; RH1, 5′-TCG ACG ACC TGC
AGC CAA GCT AGC T-3′; primers for long homologous arm:
FH2, 5′-GCT TTA CGG TAT CGC CGC TCC CGA TTC G-3′;
RH2, 5′-CCC CTG GCT GCC TGC GGG TAG C-3′. In positive
clones selected for blastocyst (C57BL/6) injection the integrity
of recombined sequence was veriﬁed by sequencing. Chimeric
males were paired with C57BL/6 mice. Heterozygous oﬀspring
were paired with mice expressing Cre recombinase [TgN(EIIa-
Cre)C5379Lmgd, H. Westphal, NIH Bethesda, USA] to remove
the neo selection marker. Resulting heterozygous oﬀspring were
interbred to obtain homozygous mutants (Cav1.3DCRDHA/HA)
as well as wild-type (WT) littermates. Age-matched littermates
were used for all experiments. For genotyping the following PCR
primers were used (Figure 2): forward F1: 5′-TCT GTG CTA
CGT CCC CAG TGC T-3′; reverse: R1: 5′-GCA GCA CTA GCG
TAA TCT GGA ACA T-3′; R2: 5′-CGT GCC CGT CTC TGG
CTG GA-3′ (WT allele: 535 bp, mutated allele: 332 bp + 678 bp).
RNA Isolation, Reverse Transcription and Qualitative
PCR Analysis in IHCs and OHCs
RNA and cDNA samples were obtained from adult male
mouse IHCs and OHCs. Reverse transcription of 40 individually
collected IHCs or 120 OHCs in a reaction volume of 20 μl
was carried out with the SuperScript III Reverse Transcriptase
(Fermentas), dNTP (New England Biolabs), random hexamer
primers (Invitrogen), RNaseOUT (Invitrogen), dithiothreitol and
nuclease free water (Promega). PCR (94◦C for 1 min, 40 cycles of
94◦C for 30 s, 58◦C for 30 s, 72◦C for 1 min) was performed with
3 μl of the reverse transcription product in a reaction volume of
25 μl with the PCR Master Mix (2x) (Fermentas) and 0.4 μM
primer. The following primers within exon 42 and exon 45 were
used to amplify a 624 bp stretch for transcripts containing exon
43L or 470 bp for exon 43S (fwd: 5′-GGG CCA GAA ATC CGA
CGG GC-3′; rev: 5′-TCC AGG TGG GAG AGC TGT CGT-3′).
To obtain detectable PCR products (43L: 557 bp; 43S: 403 bp) a
second (nested) PCR (25 cycles, same program) with 0.2 μl of
the ﬁrst PCR product as template with exon 42 and 45-speciﬁc
primers was necessary (fwd: 5′-ACG AGC CAG AAG ACT CCA
AA-3′; rev: 5′-CAC AGC ACT CCT CGC TAC TG-3′). 0.15 ng
RNA equivalent of whole brain and of whole heart cDNA served
as positive controls.
Primary Antibodies
Anti-HA, high aﬃnity rat monoclonal antibody (3F10, Roche,
1:200) or Alexa488-conjugated antibody (mouse, Invitrogen);
anti-Cav1.3α1CT, aﬃnity-puriﬁed polyclonal antibody directed
against amino acids 2022-2138 (GenBank accession M76558;
Platzer et al., 2000); anti-Cav1.3α1NT (Ab144, Jenkins et al.,
2010); anti-CtBP2/ RIBEYE (rabbit, Cell Applications); anti-
Cav1.3 (rabbit, Alomone); anti-Cavβ2 (rabbit, kindly provided by
V. Flockerzi, Saarland University).
Protein Preparations from Transfected tsA-201
Cells and Mouse Whole Brain
For preparation of membranes medium was removed 3 days
after transfection and cells were washed with ice-cold PBS
(phosphate buﬀered saline, 137 mM NaCl, 2.7 mM KCl, 8 mM
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Na2HPO4 × 2H20, 1.5 mM KH2PO4, ) and harvested by
scraping. The cells were resuspended in 2 ml lysis buﬀer
(10mMTris-HCl, 1μg/ml aprotinin, 0.1mg/ml trypsin inhibitor,
1 μM pepstatin A, 0.5 mM benzamidine, 0.2 mM PMSF
(phenylmethylsulfonyl ﬂuoride), 2 mM iodacetamide, 1 μl/ml
leupeptin) and kept on ice for 15 min. Cells were resuspended
by pipetting up and down 50 times and subsequently passed
through a cannula (27 G) four times. After centrifugation
for 20 min at 726 × g the supernatant was transferred into
ultracentrifugation tubes. Ultracentrifugation was carried out in
a L-60 ultracentrifuge at 110 561 × g for 30 min. The pellet
was dissolved in 150–200 μl lysis buﬀer, and 50 μl aliquots were
shock frozen in liquid nitrogen and stored at −80◦C. Total cell
lysates of transfected tsA-201 cells were prepared by adding 150–
200 μl ice-cold cell lysis buﬀer (50 mM Tris·HCl pH 7.4, 150 mM
NaCl, 1 mM EDTA, 1 % (v/v) Triton X-100, supplemented
with protease inhibitors as above) to collected cells and slow
rotation at 4◦C for 20 min. Insoluble cell debris was removed by
centrifugation for 15 min (16 600 × g) at 4◦C. Aliquots of the
lysate were shock frozen in liquid nitrogen and stored at −80◦C.
Membrane protein preparation from adult mouse brain was
performed as described (Pichler et al., 1997).
SDS-PAGE and Western Blotting
Protein in sample buﬀer was denatured under reducing
conditions at 57 ◦C for 15 min. Samples and prestained
molecular weight marker (Precision Plus Protein All Blue
Standards, Biorad) were separated on polyacryamide gels (5,
12% gels; or 4-15% gradient gels) in 25 mM Tris Base,
192 mM glycine, 0.1% SDS. Separated proteins were blotted
on polyvinylidene ﬂuoride (PVDF) membrane [Immobilon-P
Transfer membrane, Millipore; transfer buﬀer: 25 mM Tris
base, 192 mM glycine, 20% (v/v) methanol, with or without
0.1% (w/v) SDS]. Coomassie staining of gels was performed
to check for eﬃciency of the transfer. Immunostained bands
were visualized using Pierce ECL Western Blotting Substrate
(Thermo Scientiﬁc) and a Fusion Fx7 Peqlab bioimager.
Quantitation of band intensity was performed with Image J
1.46 (National Institute of Health). For quantiﬁcation integrated
density of speciﬁc bands was normalized against loading control.
Unspeciﬁc bands and Coomassie-stained membranes were used
as loading control. Quantiﬁcation of gel or blot intensities
was performed with data obtained within a linear range of
exposure.
Immunohistochemistry
Cochleae of hearing Cav1.3DCRDHA/HA mice and WT
littermates (aged 3–11 weeks) were ﬁxed by injection of
Zamboni’s ﬁxative into the round and oval window and
incubation for 8 min on ice, followed by rinsing with PBS. The
organ of Corti was dissected and mounted on a slide using
CellTak (BD Bioscience). Whole-mounts were stained using
the following solutions: PBS, blocking buﬀer (1% BSA in PBS),
permeabilization buﬀer (0.5% Triton X-100 in PBS), reaction
buﬀer (0.5% BSA, 0.2% Triton X-100 in PBS), washing buﬀer
(0.1% Triton X-100 in PBS). Whole-mounts were embedded
with Vectashield mounting medium with DAPI (Vector UK)
and viewed using a confocal Zeiss LSM 700. Whole-mounts
were double-labeled by simultaneous incubation of an Alexa488-
conjugated anti-HA antibody and antibodies directed against
Cav1.3, CtBP2/RIBEYE or Cavβ2 (see above), which were
detected using a Cy3-conjugated secondary antibody (Jackson
Immunoresearch).
Electrophysiological Recordings in tsA-201
Cells
Cell culture, transfection and electrophysiological recordings
were performed as described previously using 15 mM Ca2+
as charge carrier (Singh et al., 2008; Lieb et al., 2014).
Recording solutions [in mM]: extracellular (bath) solution: 15
CaCl2, 10 HEPES, 150 choline-Cl, 1 MgCl2, adjusted to pH
7.4 with CsOH and intracellular (pipette) solution: 135 CsCl,
10 Cs-EGTA, 1 MgCl2 adjusted to pH 7.4 with CsOH. The
voltage-dependence of activation was determined from current–
voltage (I–V) – relationships obtained by step depolarizations
from a holding potential of −80 mV to various test potentials.
Data were ﬁtted to the equation:
I = Gmax(V− Vrev)/(1 + exp[(V0.5 − V)/kact]),
where Vrev is the extrapolated reversal potential of ICa, V is the
membrane potential, I is the peak current, Gmax is the maximum
conductance of the cell, V0.5 is the voltage for half maximal
activation and kact is the slope factor of the Boltzmann term.
Data were corrected for the liquid junction potential (8.5 mV).
The time course of Ca2+ current inactivation (ICa) was assessed
during a 5-s depolarizing testpulse to the voltage of maximal
current inﬂux (Vmax). The percentage of ICa inactivation was
calculated at various time points (30 and 250 ms, 1 and 5 s).
Electrophysiological Recordings in IHCs
Recordings were performed on mature apical turn IHCs from
P18–P21 Cav1.3DCRDHA/HA mice and their WT littermate
controls. Animal procedures were approved by the Saarland
University. Animals were killed by decapitation in accordance
with national ethical guidelines. Organs of Corti were dissected
and kept in extracellular solution with reduced Cl− concentration
containing (in mM): 70 NaOH·lactobionate, 83 NaCl, 5.8
KCl, 1.3 CaCl2, 0.95 MgCl2, 5.3 glucose, 10 HEPES, 0.7
NaH2PO4 (pH = 7.35; 320 mosmol kg−1). Ca2+ currents
were recorded during superfusion with (in mM): 10 CaCl2, 35
tetraethylammonium (TEA) chloride, 15 4-aminopyridine (4-
AP) and 100 μM linopirdine in order to block K+ currents.
Ba2+ currents were recorded in extracellular solution containing
(in mM): 72.5 NaOH·lactobionate, 40 NaCl, 0.9 MgCl2, 5.6
glucose, 10 HEPES, 10 BaCl2, 35 TEA, 15 4-AP (pH = 7.35;
320 mosmol kg−1). For all experiments quartz pipettes were
used ﬁlled with (mM): 110 Cs+ methane sulfonate, 20 CsCl,
10 Na+ phosphocreatine, 5 HEPES, 5 EGTA, 4 MgCl2, 4
Na2ATP, 0.1 CaCl2, 0.3 GTP (pH 7.35, 305 mosmol kg−1).
Whole-cell patch clamp recordings were performed at room
temperature using an Optopatch (Cairn Research, Faversham,
UK) and an AXOPATCH 200B ampliﬁer (Molecular Devices,
Palo Alto, CA, USA). Ca2+ and Ba2+ currents were corrected
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oﬄine for linear leak currents and for potentials by subtracting
their respective liquid junction potential (6 mV for Ca2+
currents; 8 mV for Ba2+ currents; for data acquisitions see
also Michna et al., 2003). Ca2+ (Ba2+) currents were elicited
by 8 ms long depolarizing voltage steps from −99 mV to
+46 mV (−97 mV to +48 mV) with 5 mV increments. I-V
relations were calculated as the average current taken from the
last ms of the voltage steps as a function of the respective
voltage. Fits of I–V curves were performed as described (Pirone
et al., 2014), yielding the voltage of half-maximum activation
(V0.5) und the slope (kact) as a measure of voltage-sensitivity.
Inactivation was measured by applying 400 ms long depolarizing
steps to the voltages stated above with 10 mV increments.
Currents at the voltage of maximum activation were ﬁtted
with a double-exponential function (Ca2+ currents) or a mono-
exponential function (Ba2+ currents), respectively (Michna
et al., 2003). For normalization, respective current values were
divided by the peak current value at the starting point of the
ﬁt.
Electrophysiological Recordings in Chromaffin
Cells
Isolation and culture of chromaﬃn cells was performed as
described (Marcantoni et al., 2010). Currents were recorded
in perforated-patch conditions (Cesetti et al., 2003) using
a multiclamp 700-B ampliﬁer and pClamp 10.0 software
(Molecular Devices, Sunnyvale, CA, USA). Traces were ﬁltered
using a low-pass bessel ﬁlter set at 1–2 kHz and sampled
at 10 kHz using a digidata 1440 A acquisition interface
(Molecular Devices, Sunnyvale, CA, USA). Borosillicate glass
pipettes (Kimble Chase Life Science, Vineland, NJ, USA) with
a resistance of 2–3 M were dipped in an Eppendorf tube
containing intracellular solution before being back-ﬁlled with the
same solution containing 500 μg/ml of amphotericin B (Sigma
Aldrich, Munich, Germany), dissolved in DMSO (Sigma Aldrich,
Munich, Germany). Recordings were initiated after amphotericin
B brought the access resistance below 15 M (5–10 min)
(Cesetti et al., 2003). Series resistance was compensated by
80% and monitored throughout the experiment. Fast capacitive
transients during step-wise depolarisations (in voltage-clamp)
were minimized online by the use of the patch-clamp analog
compensation. Uncompensated capacitive currents (in voltage-
clamp) were further reduced by the subtraction of the averaged
currents in response to P/4 hyperpolarising pulses. Intracellular
solution used for Ca2+ and Ba2+ current measurements was
composed of (in mM) 135 Cs-MeSO3, 8 NaCl, 2 MgCl2 and 20
HEPES, pH 7,4 (with CsOH). The extracellular solution used
was composed of (in mM) 135 TEA-Cl, 2 CaCl2 or 2 BaCl2,
2 MgCl2, 10 HEPES, 10 glucose, pH 7.4 (with TEA-OH). TTX
(300 nM; Tocris Bioscience: Bristol, UK)) was added to avoid
contamination by Na+ currents. L-type currents were obtained
by subtracting the nifedipine (3 μM) - resistant component from
total Ca2+ currents (Marcantoni et al., 2010). Solutions were
perfused using a gravity based perfusion system. For current-
clamp recording external solution consisted of (in mM): 130
NaCl, 4 KCl, 2 CaCl2, 2 MgCl2, 10 HEPES and 10 glucose; pH
7.4 (with NaOH). The intracellular solution consisted of (in mM)
135 KAsp, 8 NaCl, 20 HEPES, 2 MgCl, 5 EGTA, pH 7.4 (with
NaOH).
Brain Slice Electrophysiology
Brains from neonatal mice (P10–P15) were extracted shortly
after decapitation. They were acutely sliced with a vibratome
while submerged in highly oxygenated and chilled artiﬁcial
cerebrospinal ﬂuid (Dragicevic et al., 2014). Slices (250 μm)
were stored in oxygenated ACSF at room temperature.
Electrophysiological measurements were carried at 36◦C in cell-
attached conﬁguration. Patch pipettes had a resistance of 6–
8 M and contained (in mM): 132 K-gluconate, 1 EGTA, 2
MgCl2, 2 NaCl, 10 HEPES, 2 MgATP, 2 NaGTP and 1 mg/ml
biocytin. The pH of 7.2 was balanced with tetraethylammonium
hydroxide. ACSF contained (in mM): 125 NaCl, 26 NaHCO3, 2.5
KCl, 1.25 NaHPO4, 2 CaCl2, 2 MgCl2. The pH of 7.4 was reached
by saturating the ACSFwith carbogen. The glucose concentration
in ACSF was 25 mM for preparation and storage and 10 mM
during the electrophysiological recordings. To block fast synaptic
transmission, 10 μM DNQX (6,7 dinitroquinoxaline-2,3-dione,
Tocris) and 10 μM gabazine (SR95531 hydrobromide, Tocris)
were added to artiﬁcial CSF.
Hearing Measurements
Auditory brainstem responses (ABR) and distortion product
otoacoustic emissions (DPOAE) were recorded in anesthetized
mice aged 3–5 weeks as described (Engel et al., 2006;
Ruttiger et al., 2013). For anesthesia a mixture of ketamine-
hydrochloride (75 mg/kg body weight, Ketavet 100, Pharmacia,
Karlsruhe, Germany) and xylazine-hydrochloride (5 mg/kg body
weight, Rompun 290, Bayer, Leverkusen, Germany) was injected
intraperitoneally with an injection volume of 5 ml/kg b.w.
Anesthesia was maintained by subcutaneous application of 1/3 of
the initial dose, typically in 30 min intervals. Body temperature
was maintained with a temperature-controlled heating pad. ABR
thresholds were determined with click (100 μs) or pure tone
stimuli (3 ms + 1 ms rise/fall time, 2–45 kHz) with electrodes
placed at the ear (positive) and vertex. Cubic 2∗f1−f2 DPOAE
amplitudes for the two stimulus primaries with frequencies f1 and
f2 and f2 = 1.2∗f1, and sound pressure level L1 = 55 dB SPL and
L2= 45 dB SPL for the ﬁrst and the second primary, respectively,
were measured in the range between 10 and 18 kHz using 0.5 kHz
steps followed by averaging (Schimmang et al., 2003; Hecker et al.,
2011).
Homecage Activity
Homecage activity was quantiﬁed using an automated system
(Inframot; TSE, Bad Homburg, Germany) over a period of
two light cycles and three dark cycles as previously described
(Singewald et al., 2004; Cole et al., 2008). Measurement was
started at the beginning of the dark cycle after 12 h of habituation.
Eight animals were tracked simultaneously, each in a type
3Makrolon cage (265× 150× 420 mm) by sensing the body heat
image (infra-red radiation) and its spatial displacement over time.
No movements were monitored when the mice were inactive,
sleeping or during moderate self-grooming. Data were collected
in bins of 1 min and were subsequently pooled to 1-h intervals.
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Statistics
Data analysis was performed using Clampﬁt 10.2 (Axon
Instruments), Sigma Plot 11 (Systat Software Inc.), Statistica
8.0, Origin 6.0 or Igor Pro 6.12. All values are presented as
mean± SE for the indicated number of experiments (n), except if
stated otherwise. Data were analyzed by unpaired Student’s t-test
(Welch’s test for diﬀering variances), Mann–Whitney test, or one-
way ANOVA followed by Bonferroni post hoc test as indicated
using Graph Pad Prism 5.1 software (GraphPad Software Inc.).
Results
HA-Tag in DCRD Disrupts Functional CTM in a
Recombinant Cav1.3 Channel Construct
We ﬁrst inserted a hemagglutinin (HA)-tag into the recombinant
mouse Cav1.3 α1-subunit (long splice variant, mCav1.3L)
and veriﬁed that this strategy disrupts CTM modulation in
transfected tsA-201 cells (Figure 1). In this construct (mCav1.3L-
HA) we replaced critical negative charges within the DCRD
region (amino acids DEME, Singh et al., 2008; see Materials and
Methods and Figure 1D) with a sequence encoding the HA-
epitope without truncating the C-terminus. mCav1.3L-HA fully
reproduced the gating behavior of short Cav1.3 splice variants
(Bock et al., 2011). Compared to WT Cav1.3 Ca2+ currents
(ICa), mCav1.3L-HA currents exhibited signiﬁcantly stronger
voltage-dependence of activation (Figure 1A), faster inactivation
(Figures 1B,C) and higher current densities (Table 1). As in
short Cav1.3 splice variants, mCav1.3L-HA ON-gating currents
were absent or only small despite robust inward ICa, due
to the higher open probability of short Cav1.3 channels
(Figure 1C; Bock et al., 2011; Lieb et al., 2014). These data
demonstrate that the HA-insertion in the DCRD successfully
blocked CTM function and conferred the biochemically long
Cav1.3 channel isoform with gating properties expected for
short isoforms. Introduction of the HA-tag did not interfere
with eﬃcient α1-subunit expression as a full- length protein
in tsA-201 cells (221 kDa ± 7 kDa, SD, n = 3). In the
mutant C-terminus still all other functional domains, including
a PDZ-binding motif at the C-terminal end (Jenkins et al.,
FIGURE 1 | Activation and inactivation properties of ICa through
mCav1.3L and mCav1.3L-HA channels. (A) α1-subunits were
heterologously expressed in tsA-201 cells together with β3 and α2δ1
(at least three independent transfections). Whole-cell patch-clamp
current–voltage relationship obtained by depolarizations from a Vh of
−80 mV to the indicated test potentials in cells transfected with
mouse wild-type (WT) Cav1.3 (mCav1.3L, black) and mCav1.3L-HA
(blue). All data were junction potential – corrected. (B) Percent ICa
inactivation (15 mM Ca2+ ) during a test pulse from −80 mV to the
Vmax. ∗∗∗p < 0.001; ∗∗p < 0.01 (one-way ANOVA analysis followed
by Bonferroni post-test). Data are means ± SE (error bars often
smaller than symbols). For gating parameters, n-numbers and statistics
see Table 1. (C) Normalized ICa recordings in tsA-201 cells expressing
mCav1.3L or mCav1.3L-HA channel complexes. Cells were depolarized
for 10 s from −90 mV to Vmax. The inset shows the first 50 ms of
the test pulse. Notice the transient at the beginning of the pulse
reflecting ON gating currents which were prominent in mCav1.3L but
absent or barely visible in Cav1.3DCRDHA (indicating higher open
probability of short Cav1.3 α1-isoforms in agreement with our previous
findings; Bock et al., 2011; Lieb et al., 2014). Cells 1005090023,
1804090028. (D) To disrupt CTM function residues DEME (amino acids
2073-2076; NCBI accession number EU363339) were replaced by a
single 9-residue HA-tag. Successful functional disruption was verified in
electrophysiological experiments (A–C). This can be explained by
removal of one of the negative charges required for interaction with
the PCRD by the HA-tag and as well as disruption of the putative
α-helical structure in this region (as predicted using secondary structure
prediction by Jpred; Cole et al., 2008).
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TABLE 1 | Biophysical properties of mCav1.3L and mCav1.3L-HA.
Parameter mCav1.3L mCav1.3L-HA p
Mean ±SD n Mean ±SD n
ICa Imax [pA/pF] 50.22 ±36.72 36 86.94 ±33.40 8 <0.01
V0.5 [mV] −4.09 ±2.47 36 −13.76 ±2.00 8 <0.0001
kact [mV] 8.87 ±0.66 36 6.94 ±0.81 8 <0.0001
Inactivation [%] 66.26 ±11.17 30 88.16 ±1.95 7 <0.0001
τfast [ms] 14.92 ±3.65 30 12.63 ±1.98 7 0.0156
τslow [ms] 207.23 ±77.25 30 117.39 ±16.27 7 <0.0001
Afast 0.23 ±0.12 30 0.75 ±0.02 7 <0.0001
Aslow 0.64 ±0.11 30 0.15 ±0.01 7 <0.0001
Non-inact 0.13 ±0.04 30 0.10 ±0.01 7 <0.0001
Cav1.3 channels were expressed in tsA-201 cells and activation parameters were obtained from I–V curves fitted as described in methods. V0.5, voltage of half-maximum
activation; kact, steepness of activation curve; Inactivation %, percent inactivation 250 ms after time of peak current. Non-linear curve fits to a double-exponential function
revealed time constants for fast (τfast) and slow (τslow) inactivation during 300 ms, and the fraction of ICa normalized to Imax with fast (Afast) and slow (Aslow) inactivation
and of a non-inactivating component (non-inact). Data were fitted to a double-exponential function. Welch’s t-test was performed for statistical analysis.
FIGURE 2 | Gene targeting strategy to generate Cav1.3DCRDHA/HA
mice. (A) PCR primer positions for genotyping (see Materials and
Methods) are indicated. WT allele, mutated allele and mutated allele after
neo excision are shown. DEME, single amino acid letter code for
negatively charged DCRD sequence replaced by HA-tag as indicated. F1,
R1, R2 indicate forward and reverse primers used for genotyping.
(B) Genotyping reactions yielding the expected fragment sizes are shown
for WT, hetero- (Het) and homozygous (HA) mutant mice. (C) Hourly time
course of home cage activity in HA (n = 10, gray) and WT mice
(n = 11, black) recorded over three consecutive dark and two light
cycles as described in Methods. Black bars indicate dark periods. Data
are presented as Mean ± SE.
2010) are preserved. Since the genetic modiﬁcation aﬀects the
last exon and the remaining loxP site is located in the 3′-
UTR alternative splicing of the channel should not be aﬀected.
Mice containing this modiﬁcation should therefore only report
changes resulting from altered channel gating induced by CTM
disruption.
Generation of Cav1.3DCRDHA/HA Mice
We introduced the identical modiﬁcation of the DCRD region
in exon 49 of the murine cacna1d gene (Figure 2). The resulting
homozygous mutants (Cav1.3DCRDHA/HA mice; neo-cassette
removed) were viable and showed normal sexual activity and
reproduction. No gross anatomical or behavioral abnormalities
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were observed. Litters from heterozygous mice showed normal
Mendelian inheritance. The mutation did not aﬀect spontaneous
locomotor activity (homecage activity, Figure 2C).
Short and Long Cav1.3 α1-Variants are
Expressed in Mouse Brain
First we conﬁrmed that the HA-tagged Cav1.3 α1-subunit
is expressed as a full-length protein in vivo and that the
HA-tag did not alter the level of overall Cav1.3 α1 protein
expression. Western blot analysis of whole brain homogenates
(n > 3, Figure 3) immunostained with a C-terminal antibody
(anti-Cav1.3α1CT; Platzer et al., 2000) revealed equal Cav1.3
α1-subunit expression levels in homozygous mutants
(Cav1.3DCRDHA/HA: 111% ± 19%; mean ± SD, n = 3) as
compared to their WT littermates (Figure 3A). Speciﬁcity of the
antibody was demonstrated in Cav1.3−/− brains analyzed in
parallel.
In previous reports two size forms of Cav1.3 α1-subunits
were detected in rodent brain (Hell et al., 1993; Calin-Jageman
et al., 2007). Since anti-Cav1.3α1CT (directed against the distal
C-terminus) and anti-HA antibodies only bind to the long Cav1.3
splice variant, an N-terminal antibody recognizing all Cav1.3 α1
subunits (anti-Cav1.3α1NT) in postnatal brain was employed to
quantify the presence of shorter variants. In addition to the HA-
tagged α1 (apparent mass 231 kDa, Figure 3) this antibody also
speciﬁcally detected a shorter α1-subunit variant (177 kDa, n= 6)
of equal staining intensity and no change in the ratio of the two
size forms in Cav1.3DCRDHA/HA mice (Figure 3B; long species:
WT: 49 ± 8% of total immunoreactivity; Cav1.3DCRDHA/HA,
47± 5%;mean± SD, n= 6). The absence of a smaller HA-stained
species (Figure 3A) ruled out that short forms (detected with
anti-Cav1.3α1NT in Figure 3B) contain exon 49 sequence and
must therefore correspond to C-terminally short variants lacking
a DCRD domain. The two α1-species identiﬁed in brain migrated
with slightly larger apparent molecular masses (231 and 177 kDa,
Figure 3B) than the recombinant long (L) and short (43S,
Cav1.343S, Bock et al., 2011) α1-subunits separated on the same
gel (221 and 162 kDa, L and 43S, arrows in Figure 3B). Because
diﬀerences in glycosylation are unlikely (tsA-201 cells allow
eﬃcient glycosylation) we propose that the Cav1.3 α1-subunits
in brain extensively utilize additive alternative splicing of exons
not present in our recombinant constructs (such as exons 11,
32, and 44). Although absolute molecular masses are diﬃcult to
determine due to the abnormal migration of Ca2+ channel α1-
subunits in SDS-PAGE (Glossmann et al., 1988), the diﬀerence
between the long and short brain α1-subunit bands (brain:
54 kDa) is close to the calculated (53 kDa; Cav1.3L 244 kDa;
Cav1.343S 191 kDa; Bock et al., 2011) and measured (tsA-201
cells: 59 kDa) molecular mass diﬀerence between Cav1.3L and
Cav1.343S.
No Evidence for a Stable C-Terminal
Proteolytic Fragment in Mouse Brain
The short Cav1.3 α1-subunit species could arise either from
alternative splicing or from C-terminal post-translational
proteolytic processing thereby generating stable C-terminal
peptides as demonstrated for CaV1.1 and Cav1.2 α1-subunits
(Hulme et al., 2005, 2006; Gomez-Ospina et al., 2006). If this
was also the case for Cav1.3 α1 in brain, then one or more
smaller HA-tagged C-terminal peptides should be detectable
in mutant mice. Cleavage at the proposed site of Cav1.1
and Cav1.2 α1 subunit (amino acid 1800, NCBI reference
NP_001242928.1; Hulme et al., 2005, 2006), well conserved
in Cav1.3, would lead to a 399 amino acid peptide (45 kDa),
whereas a fragment accounting for the mass diﬀerence of the
two size forms would lead to a 53 kDa peptide. Neither anti-HA
(brain homogenate or brain membranes; comparison against
WT; Figures 4A,B) nor anti-Cav1.3α1CT antibodies (comparison
FIGURE 3 | Western blot analysis of α1-subunits in WT and mutant
mouse brain homogenates. (A) Proteins (100 μg/lane) were separated
on 5% SDS page and immunostained with polyclonal antibody Cav1.3
α1CT. The Cav1.3 α1 subunit was specifically detected as a 231 kDa
protein at expression levels indistinguishable between WT and homozygous
mutants (HA) (see Results). KO, Cav1.3− /− negative control. (B) Same
separation as in A (100 μg/lane) but detection with anti-Cav1.3α1NT. The
migration of recombinant mCav1.3L (L) and mCav1.343S (43S) on the
same gel (not shown) and their calculated molecular mass are indicated by
arrows (left). Migration of molecular mass standards as well as the brain
long and short α1-subunit species are also indicated (right). An unspecific
∼120 kDa band served as loading control. One representative experiment
of at least three independent experiments is shown for all panels. KO,
Cav1.3−/−; HA, Cav1.3DCRDHA/HA, WT, wild-type littermate.
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FIGURE 4 | Absence of smaller C-terminally–derived Cav1.3 α1
fragments in WT and Cav1.3DCRDHA/HA brain preparations.
(A) Mouse brain homogenate (100 μg of protein/lane) prepared from WT
or Cav1.3DCRDHA/HA (HA) mice were separated on 4–15% gradient
SDS-PAGE and immunostained with anti-HA antibody. The blot was
overexposed to also visualize less abundant smaller fragments. in
separate experiments α1- associated HA-immunoreactivity could be
detected with only 10% (10 μg/lane) of the protein amount used (n = 3)
demonstrating the sensitivity of the assay. (B) Mouse brain membranes
(100 μg of protein/lane) were analyzed as in (A). (C) Mouse brain
membranes (100 μg of protein/lane) from WT or Cav1.3−/− (KO) mice
were blotted as in (B) and stained with anti-Cav1.3α1CT antibodies. To
some WT samples (33 μg/lane) a 45 kDa recombinant C-terminal control
peptide was added (arrow, amounts indicated) before separation to
demonstrate successful transfer and sensitive detection as a positive
control for sensitivity.
against knockout control, Figure 4C) speciﬁcally detected smaller
candidate peptides (three independent experiments from three
diﬀerent brain preparations). However, in control experiments
anti-Cav1.3α1CT speciﬁcally recognized small amounts of a
recombinant C-terminal Cav1.3 fragment (C-terminal 158
residues fused to GFP, 45 kDa, Singh et al., 2008) added to brain
preparations before SDS-PAGE serving as a positive control for
assay sensitivity (Figure 4C).
Taken together, we obtained no evidence for the presence of
a stable HA-labeled C-terminal cleavage product. Instead, our
experiments are in good agreementwith our previous ﬁnding that
about half of the Cav1.3 α1-subunit transcripts in brain encode
short splice variants of almost identical size (mainly Cav1.342A
and Cav1.343S, Bock et al., 2011). Although contribution by
proteolytic processing cannot be ruled out, our biochemical
data using Cav1.3DCRDHA/HA mice strongly indicate that the
majority of short α1-subunit species is derived from alternative
splicing.
Role of Long Cav1.3 Channels for IHC Function
and Hearing
To study the role of CTM function in intact cells we focused
on IHCs and MCCs. In these cells the contribution of Cav1.3
current components to total ICa has been well deﬁned (Platzer
et al., 2000; Brandt et al., 2003; Marcantoni et al., 2010; Vandael
et al., 2012). Moreover, the extent of CDI is very diﬀerent in the
two cell types because CaBPs strongly inhibit CDI in IHCs (Yang
et al., 2006; Cui et al., 2007; Schrauwen et al., 2012) but not in
chromaﬃn cells (Marcantoni et al., 2010). In addition, transcripts
for both long and short Cav1.3 α1 splice variants are expressed in
MCCs (Marcantoni et al., 2010) and, as shown in Figure 5, also
in individual IHCs and OHCs.
We veriﬁed the presence of HA-tagged Cav1.3 channels
in IHCs by whole-mount immunolabeling of adult
Cav1.3DCRDHA/HA organs of Corti with anti-HA antibodies
using WT littermates as negative control (Figure 6). HA-labeled
structures co-localized with immunolabeled Cav1.3 and Cavβ2,
the main auxiliary β-subunit in IHCs (Figures 6A,C; Neef
et al., 2009). In control experiments of WT specimens no
comparable HA-immunoreactivity was observed demonstrating
the speciﬁcity of the anti-HA antibody (Figure 6B). The anti-
Cav1.3 antibody used (Alomone Labs, Israel) recognizes a
stretch in the cytoplasmic II–III loop and thus detects the full
length Cav1.3 channel (including HA-tagged channels) as well
as C-terminally short isoforms (such as Cav1.343S). The close
corresponding staining of anti-Cav1.3 and anti-HA suggests
that in adult IHCs all Cav1.3 clusters contain long Cav1.3
(Figure 6A). HA-tagged channels of mature IHCs were localized
in very close apposition to synaptic ribbons as demonstrated by
co-labeling with anti-CtBP2 (C-terminal binding protein 2), a
speciﬁc marker for ribbon synapses (Figure 6D), indicating that
long splice variants are present at all ribbon synapses.
To test if the disruption of CTM aﬀects IHC Ca2+ currents,
we performed patch-clamp recordings of mature IHCs with
either 10 mM Ca2+ (ICa, Figures 7A–E) or 10 mM Ba2+
(IBa, Figures 7F,G) as charge carrier to also quantitate CDI.
Depolarizations to the indicated voltages resulted in fast
activating and deactivating inward currents for both genotypes.
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FIGURE 5 | Cav1.3 α1 transcripts containing exons 43S and 43L in mouse
IHCs and OHCs, at P6 and P22 using nested PCR. Fragments containing
43S (403 bp) or 43L (557 bp) were amplified using nested PCR (see Materials
and Methods) with primers specific for exon 42 (forward) and 45 (reverse) of
mouse Cav1.3. S1–S14 represent samples from independent preparations. For
each cell type and developmental stage at least three independent experiments
were performed. Whole brain (WB) and heart (WH) served as positive controls,
H2O (no template) as negative control. Specificity of PCR products was
confirmed by sequencing. When two independent PCR reactions with three
different RNA samples of each cell type were performed, the number of
successful detections for each transcript was as follows: detection of 43L: 6
(out of six experiments) in IHC and OHC preparations of all developmental
stages; detection of 43S: 4 (6) in IHC P06 and IHC P22, 6 (6) in OHC P06 and 5
(6) in OHC P22. Bp, basepair markers.
FIGURE 6 | Comparison of the protein localization of anti-HA-labeled
Cav1.3 with immunolabeled Cav1.3, Cavβ2 and CtBP2/RIBEYE in IHCs.
(A–D) Whole-mount preparations of apical turns of the organ of Corti from adult
Cav1.3DCRDHA/HA (A,C,D) and WT (B) mice were co-immunolabeled with
anti-HA and anti-Cav1.3 (A, B, 11 weeks), anti-HA and anti-Cavβ2 (C, P28), or
anti-HA and anti-CtBP2/RIBEYE antibodies (D, P37). Every image shows the
basolateral poles of two adjacent IHCs the nuclei of which are indicated by
asterisks in the rightmost column, respectively. HA staining (A1,C1,D1) largely
overlapped with Cav1.3 (A2), Cavß2 (C2) and CtBP2 (D2) staining at the basal
poles of IHCs as evident upon merging corresponding images (A3,C3,D3). In
the WT, no specific HA-labeling (B1) was present at the position of Cav1.3
labeling (B2,B3). The weak ‘cloudy’ green anti-HA staining was present in all
specimen investigated and therefore considered unspecific. Cell nuclei of IHCs
were counterstained with DAPI (blue). 1 of 3 (A, age: 2–3 months), 1 of 4 (B,
age: P25 – 3 month), 1 of 5 (C, P25–P31) and 1 of 5 (D, P28–P37) independent
experiments is illustrated, respectively. Scale bars: 5 μm.
Peak ICa amplitudes and ICa current densities were signiﬁcantly
larger in Cav1.3DCRDHA/HA IHCs as measured in averaged I–V
relations (Figure 7B;Table 2). Membrane capacitance, a measure
for IHC size, and parameters of ICa and IBa activation obtained
from I–V relations (half-maximal activation voltage, slope of
current activation) were not signiﬁcantly altered (Table 2).
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FIGURE 7 | Ca2+ and Ba2+ currents in adult IHCs (P18–21) of
Cav1.3DCRDHA/HA and WT littermates. (A) Selected ICa traces (10 mM
Ca2+ ) of a WT (black) and a Cav1.3DCRDHA/HA (HA, gray) mouse IHC after
depolarization from a holding potential of −86 mV for 8 ms to the indicated
voltages. (B) Corresponding averaged I–V curves from 10 WT (black,
mean + SD) and 12 Cav1.3DCRDHA/HA IHCs (gray, mean – SD) taken
between 7 and 8 ms after start of the depolarizing pulse. (C) Representative
traces of ICa inactivation of WT (black) and a Cav1.3DCRDHA/HA (gray) IHC
during a 300-ms depolarizing step to Vmax. The arrow indicates the early
phase with faster inactivation absent in Cav1.3DCRDHA/HA and in Ba2+
recordings. (D) Parameters of ICa inactivation of 8 WT and 8
Cav1.3DCRDHA/HA IHCs were obtained by fitting peak current traces from
300 – ms test pulses with a double-exponential function. Individual data
points and means (lines) are shown. The fast (τfast ) inactivation time constant
was significantly increased (p < 0.01) and showed a higher variance
between individual IHCs in Cav1.3DCRDHA/HA IHCs. (E) The slow (τslow)
inactivation time constant was not different between genotypes. (F) Averaged
I–V curves of IBa with 10 mM Ba2+ as charge carrier from 9 WT (black,
mean + SD) and 8 Cav1.3DCRDHA/HA (gray, mean – SD) IHCs between 7
and 8 ms after start of the depolarizing pulse. (G) Representative traces of
IBa inactivation of a WT (black) and a Cav1.3DCRDHA/HA (gray) IHC during a
300 ms depolarizing step to Vmax.
During longer pulses (300 ms) WT ICa inactivated with a fast
(τfast, in the range of tens of ms) and a slow time constant
(τslow, in the range of hundreds of ms) (Figures 7C–E). In
WT cells about 38% of the total current inactivated and τfast
(Afast) contributed about 25% of the inactivation (corresponding
to only about 10% of total; Table 2). In Cav1.3DCRDHA/HA
IHCs, τfast was signiﬁcantly larger (Figures 7C,D; Table 2) and
showed a larger variance than τslow suggesting that in these
IHCs the fast inactivation process was strongly reduced but not
completely abolished. τslow was not aﬀected by the mutation
(Figure 7E). Like ICa, peak IBa was also signiﬁcantly larger in
Cav1.3DCRDHA/HA IHCs (Figure 7G). Inactivation of IBa, which
mostly reﬂects VDI (Ben-Johny and Yue, 2014) was very slow
during 300-ms depolarizations, decayed monoexponentially and
did not diﬀer between genotypes (Figure 7G; Table 2). Our data
show that the small fast inactivating component in WT IHCs
represents a component of CDI that, in contrast to predictions
from studies with recombinant channels, is abolished when CTM
function is disrupted in Cav1.3DCRDHA/HA mice.
To test if these changes in current properties also aﬀect hearing
function we recorded ABR (Figure 8A) and DPOAE (Figure 8B).
Thresholds of click and frequency ABR recordings and DPOAE
amplitudes were not changed in Cav1.3DCRDHA/HA compared
with WT mice. The data indicate that reduced CDI in
Cav1.3DCRDHA/HA IHCs does not cause detectable changes in
hearing thresholds and the cochlear ampliﬁer.
Role of Long Cav1.3 Channels for Chromaffin
Cell Function
From studies in recombinant channels the increased current
amplitude in mutant IHCs was predicted whereas the slowing of
CDI was not.We therefore also studied the consequences of CTM
inhibition in MCCs. In MCCs robust CDI of L-type currents
indicates no detectable eﬀects of inhibitory CaBPs (Marcantoni
et al., 2010). In WT MCCs about 50% of the ICa is L-type (i.e.,
nifedipine-sensitive) and equally carried by Cav1.2 and Cav1.3
(Marcantoni et al., 2010). The remainder of the current is non-
L-type (P/Q-, N-, and R-type). At holding potentials of −50 mV
(near MCC resting potential) 3μMnifedipine fully blocks L-type
currents (Mahapatra et al., 2011). By subtracting the nifedipine-
resistant component from total ICa, L-type currents (ICa,L) can be
isolated (Marcantoni et al., 2010). In 2mMCa2+ ICa,L inactivated
with a fast and a slow component during 600-ms pulses to
0 mV (Figure 9A). Inactivation of IBa (2 mM Ba2+, VDI) was
much slower revealing robust CDI. Cav1.3DCRDHA/HA MCCs
showed no diﬀerences in VDI compared to WT but signiﬁcantly
faster inactivation was observed for ICa,L (Figures 9A,F). This
is evident when normalized ICa,L recordings from WT and
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TABLE 2 | Properties of IHC Ca2+ channel currents of Cav1.3DCRDHA/HA mice and wild-type (WT) littermates.
Parameter WT Cav1.3DCRDHA/HA p
Mean ± SD n Mean ±SD n
ICa Cm [pF] 9.85 ±1.23 10 10.65 ±1.77 11 0.105
Imax [pA] −102.08 ±23.20 10 −135.95 ±25.40 11 0.005
Current density [pA/pF] −10.54 ±2.86 10 −13.06 ±3.08 11 0.033
V0.5 [mV] −29.79 ±3.09 10 −29.47 ±2.70 11 0.801
Vs [mV] 11.62 ±1.15 10 11.23 ±1.15 11 0.445
Inactivation [%] 32.19 ±13.33 8 26.34 ±7.18 8 0.299
τfast [ms] 16.06 ±3.86 8 115.68 ±60.59 8 0.002
τslow [ms] 191.13 ±58.26 8 212.97 ±41.73 8 0.405
Afast, normalized [I/Imax] 0.10 ±0.04 8 0.14 ±0.05 8 0.096
Aslow, normalized [I/Imax] 0.28 ±0.10 8 0.17 ±0.06 8 0.020
Non-inactnormalized [I/Imax] 0.62 ±0.13 8 0.67 ±0.09 8 0.347
IBa Cm [pF] 8.88 ±1.74 9 10.25 ±3.20 8 0.305
Imax [pA] −186.57 ±37.49 9 −262.29 ±48.82 8 0.003
Current density [pA/pF] −21.74 ±5.73 9 −26.92 ±7.03 8 0.076
V0.5act [mV] −31.01 ±2.28 9 −31.34 ±1.67 8 0.737
Vs [mV] 11.18 ±0.89 9 10.72 ±0.67 8 0.235
Inactivation [%] 6.25 ±2.60 8 6.91 ±2.90 8 0.643
τ [ms] 375.37 ±98.37 8 410.27 ±67.43 8 0.423
Anormalized [I/Imax ] 0.12 ±0.04 8 0.14 ±0.04 8 0.379
Non-inactnormalized [I/Imax] 0.89 ±0.04 8 0.87 ±0.05 8 0.350
Cm, membrane capacitance; Imax, current at voltage of maximum activation; V0.5, voltage of half-maximum activation; Inactivation %, percent inactivation 300 ms after
time of peak current; all other parameters are as in Table 1. Student’s t-test or Mann-Whitney test were performed for statistical analysis.
FIGURE 8 | Hearing function in Cav1.3DCRDHA/HA mice. (A) ABR
thresholds (mean ± SD) of Cav1.3DCRDHA/HA mice were normal for click
stimuli (WT and Cav1.3DCRDHA/HA: n = 8/16 animals/ears) and as a
function of stimulus tone frequency (WT: n = 6/12 animals/ears and
Cav1.3DCRDHA/HA: n = 7/13 animals/ears). Thresholds could be measured in
(n = animals/ears, frequency in kHz): WT: 2/3, 2; 6/9, 2.8; 6/12, from 4 to
22.6; 3/6, 32; 3/6, 45.2; Cav1.3DCRDHA/HA: 2/3, 2; 7/13, from 2.8 to 32; 4/8,
45.2. (B) Mean DPOAE maximum amplitudes (signal to noise ratio) ± SD at
f1 = 9.1 kHz, L1 = 55 dB SPL, f2 averaged over 10–18 kHz, and L2 = 45 dB
SPL were normal in Cav1.3DCRDHA/HA (n = 7/14 animals/ears) compared
with WT mice (n = 7/14 animals/ears, p = 0.12), indicating normal function of
the cochlear amplifier.
Cav1.3DCRDHA/HA MCCs were superimposed (Figure 9B). In
Cav1.3DCRDHA/HA MCCs the degree of ICa,L inactivation was
larger both after 100 ms (WT: 32.5 ± 3.2%, Cav1.3DCRDHA/HA
47 ± 3%, p < 0.01, n = 27) and 600 ms (63.7 ± 3.3 vs.
73 ± 2.4%, p < 0.05, n = 23) (Figure 9C). Double-exponential
ﬁts of the averaged normalized traces indicated the presence
of a fast and slow inactivating component with similar time
constants in MCCs of both genotypes (see legend to Figure 9B).
However, in mutantMCCs the fractional contribution of τfast was
about twofold larger (Afast: WT: 0.14, Cav1.3DCRDHA/HA: 0.34)
with a corresponding reduction of the contribution of the slow
(Aslow) and non-inactivating component (C) (Figure 9B legend).
Similar signiﬁcant diﬀerences were obtained when individual
L-type currents were ﬁtted (Afast: WT (n = 16): −0.24 ± 0.04,
Cav1.3DCRDHA/HA (n = 22): −0.36 ± 0.04, p < 0.05; Aslow:
WT: −0.50 ± 0.06, Cav1.3DCRDHA/HA: −0.35 ± 0.04, p <
0.05; non-inactivating: WT: −0.26 ± 0.03, Cav1.3DCRDHA/HA:
−0.29 ± 0.03).
We also quantiﬁed the voltage-dependence of CDI with
a double-pulse protocol (Figures 9D,F). CDI was again
signiﬁcantly diﬀerent over a large voltage range and revealed
the CDI-typical U-shaped inactivation characteristics (Ben-Johny
and Yue, 2014) absent in IBa recordings (Figures 9E,F). Since
current densities between both WT and DCRDHA/HA MCCs
had comparable amplitude and voltage-dependence of activation
(Figure 9G) we conclude that the observed eﬀect on inactivation
is inherent to a diﬀerence in CaM-dependent CDI. Since the
current–voltage relationships comprise both Cav1.2 and Cav1.3
(or Cav1.3DCRDHA/HA) components eﬀects of the mutation on
the V0.5 cannot be reliably determined.
We have recently demonstrated a critical role of Cav1.3
activity for the generation of spontaneous action potentials (APs)
in MCCs (Vandael et al., 2010, 2012). Given the increased
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FIGURE 9 | L-type currents in MCCs from WT and Cav1.3DCRDHA/HA
mice. (A) Averaged L-type currents of WT (n = 23) and
Cav1.3DCRDHA/HA (HA, n = 27) MCCs measured in 2 mM Ca2+ (black
and red) or 2 mM Ba2+ (gray and blue) triggered by the protocol shown
on top. L-type currents were obtained by subtraction of nifedipine (3 μM)
resistant current from control traces and normalized to the peak.
(B) Superimposed L-type currents obtained in 2 mM Ca2+ from WT and
Cav1.3DCRDHA/HA MCCs. Double exponential fits of the averaged traces
(continuous curves within traces) revealed the following parameters:
Afast = −0.14, Aslow = −0.57, τfast = 23.8 ms, τslow = 397.7 ms and
C = −0.25 for WT and Afast = −0.34, Aslow = −0.46, τfast = 24.9 ms,
τslow = 382.9 ms and C = −0.20 for DCRDHA/HA MCC L-type currents.
(C) Percent inactivation of ICa after 100 and 600 ms depolarization from
Vh = −50 to 0 mV for WT (black, n = 23) and DCRDHA/HA (red,
n = 27) MCCs (∗p < 0.05; ∗∗p < 0.01, Student’s t-test).
(D) Double-pulse protocol used to evaluate Ca2+-dependent inactivation
(CDI) and representative traces in 2 mM Ca2+ of WT (black) and
Cav1.3DCRDHA/HA (red) MCCs. CDI induced by 40-ms depolarizations to
different voltages was evaluated by a test pulse to 0 mV. Test pulse
currents were normalized to maximal current amplitude obtained after
prepulses to −40 mV during which only a very small fraction of current
was activated (G). (E) Protocol as in (D) to compare inactivation in 2 mM
Ba2+ between genotypes. As for (A–C), L-type currents were obtained
by subtraction of nifedipine (3 μM) – resistant currents from total current.
(F) Top: test pulse current peaks plotted against pre-pulse conditioning
voltage. Currents were normalized against maximal peak current for WT
(n = 26, black squares) Cav1.3DCRDHA/HA (n = 22, red dots) MCCs.
Bottom: same analysis but using Ba2+ as charge carrier for WT (n = 7,
gray squares) and Cav1.3DCRDHA/HA (n = 8, blue circles) MCCs
(∗∗∗p < 0.001; ∗∗p < 0.01, two-way ANOVA followed by Bonferroni
post-test). (G) Top: current–voltage relationship of WT (black squares) and
Cav1.3DCRDHA/HA (red dots) MCCs. Bottom: normalized conductance fit
with a Boltzmann function: V0.5 = −23.3 mV, k = 6.5 mV for WT and
V0.5 = −21.9 mV, k = 6.3 mV for Cav1.3DCRDHA/HA MCCs.
rate of inactivation of Cav1.3 channels in Cav1.3DCRDHA/HA
MCCs we tested if the integrity of the CTM is important for
MCC ﬁring properties. In accordance with our previous ﬁndings
(Vandael et al., 2012) 15 out of 18 WT MCCs (83%) ﬁred
spontaneously in current-clamp with no current injection. In
contrast, only 11 out of 32 Cav1.3DCRDHA/HA MCCs (34%)
showed spontaneous APs (p < 0.001, Figure 10A). The resting
membrane potential (Vrest) was signiﬁcantly hyperpolarized by
4.4 mV in Cav1.3DCRDHA/HA MCCs as compared to WT
(p < 0.05; Figure 10A). Quiescent, spontaneous sub-threshold
oscillations of 4–6 mV lasting 0.2–0.5 s were observed in
Cav1.3DCRDHA/HA MCCs (arrows in Figure 10A), indicating
the tendency of these cells to depolarize without reaching
the threshold of AP ﬁring. This is most likely due the more
pronounced CDI decreasing the contribution of subthreshold
Cav1.3 channel activity to the net inward current driving
AP ﬁring. In spontaneously ﬁring cells the AP frequency
was not diﬀerent between both groups (1.4 ± 0.5 Hz for
Cav1.3DCRDHA/HA, 1.5± 0.3Hz forWT) and neither were other
spike parameters.
Next we used slow-ramp voltage-clamp commands (27 mV/s,
−90 to −28 mV near spike threshold) to test for the size and
time course of pacemaker currents (Ca2+, K+, Na+). These
parameters were selected since control MCCs depolarize from
about −55 to −28 mV in 1 s (1 Hz) during pacemaking. WT
MCCs (n = 9) showed signiﬁcantly larger inward currents than
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FIGURE 10 | Firing properties of WT – vs. DCRDHA/HA MCCs. (A) Left:
current-clamp traces of representative WT (black) and Cav1.3DCRDHA/HA (red)
MCCs without current injection. Dashed lines indicate baseline, dotted line
indicates 0 mV. Right: percent of firing vs. silent cells and comparison of Vrest for
WT (n = 18) and Cav1.3DCRDHA/HA (HA, n = 32) MCCs. Significance testing
on categorical data was performed by RxC contingency tables and a
chi–square test (∗∗∗p < 0.001) while a Student’s t-test was used for Vrest
(∗p < 0.05). (B) Averaged Na+, K+, and Ca2+-currents of WT (n = 9) and
Cav1.3DCRDHA/HA (n = 7) MCCs to the illustrated slow ramp protocol in the
absence (black, ctrl) or presence of nifedipine (3 μM, red) and during SK
channel block by apamin (200 nM, gray). (C) Top: overlay of WT (black) and
Cav1.3DCRDHA/HA averaged currents (red) elicited by the indicated ramp
protocol. Arrows indicate the mean Vrest of both cell populations. Bottom:
statistics for peak inward currents at about −25 mV triggered by the ramp
protocol of control traces (black), during nifedipine (red) or SK channel block by
apamin (gray) for WT (n = 9) and Cav1.3DCRDHA/HA (n = 7) MCCs (∗∗p < 0.01,
∗∗∗p < 0.001, one–way ANOVA followed by a Bonferroni post hoc analysis).
(D) Representative current-clamp traces at increasing current injections from
Vh = −70 mV from WT (black) and Cav1.3DCRDHA/HA (red) MCCs.
(E) Graphical representation of fo and fss for WT (n = 15) and
Cav1.3DCRDHA/HA (n = 16) MCCs with increasing current injections. fo, is the
first inter-spike interval frequency and fss, is the last inter-spike interval
frequency. (F) Overlay of fo and fss from (E) to highlight differences (∗p < 0.05,
∗∗p < 0.01, paired Student’s t-test).
Cav1.3DCRDHA/HA MCCs (p < 0.01; n = 9; Figures 10B,C).
These currents were eﬀectively blocked by 3 μM nifedipine
(50% for WT and 45% for DCRDHA/HA MCCs) indicating
a major contribution by LTCCs (Figure 10B). ICa activation
was shifted to more positive voltages in Cav1.3DCRDHA/HA
MCCs (red trace in Figure 10C). At pacemaker potentials,
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Cav1.3 channels are known to activate SK-channels which
dampen pacemaking and reduce the ﬁring frequency in MCCs
(Vandael et al., 2012). SK currents are able to contribute to
outward currents at relatively negative membrane potentials.
We thus investigated the contribution of SK currents during
the pacemaker cycle by applying 200 nM apamin. During
slow ramp depolarizations SK currents in Cav1.3DCRDHA/HA
MCCs were smaller than in WT (diﬀerence not signiﬁcant,
Figure 10C bottom-right). The same trend was also observed
when considering the apamin- and nifedipine-sensitive outward
tail current that follows the slow ramp (Figures 10B,C). In both
cases, the WT and Cav1.3DCRDHA/HA control traces resulted in
a net inward current that indicates a principal contribution of
Ca2+ channels to the overall pacemaking current (Figure 10C).
Less Ca2+-inﬂux at rest due tomore pronounced CDI can explain
the observed hyperpolarization of Vrest and reduced number of
spontaneously ﬁring DCRDHA/HA MCCs.
Upon injection of current pulses of increasing intensity (2–
18 pA) from a Vh of −70 mV (Figure 10D), 4 out of 16
Cav1.3DCRDHA/HA cells and 4 out of 16 WT cells started spiking
during 4 pA current injections. The ﬁring frequency at the onset
(fo) and steady-state (fss) increased with current intensity in
WT and Cav1.3DCRDHA/HA MCCs, suggesting spike frequency
adaptation in both genotypes (Figure 10E; Vandael et al., 2012).
There was no signiﬁcant diﬀerence between fo at any given
diﬀerent current intensity, while at higher current intensities
fss was signiﬁcantly higher in Cav1.3DCRDHA/HA than in WT
MCCs (Figure 10F). The origin of this phenomenon is likely
an altered Cav1.3/SK coupling mechanism. The accelerated CDI
of Cav1.3DCRDHA/HA channels is expected to recruit less SK
currents during repetitive ﬁring. This in turn would reduce the
mean outward current passing during the interspike interval with
consequent increases in the rate of ﬁring (fss).
Because a role of Cav1.3 has also been implicated in the
pacemaking of substantia nigra dopamine neurons (SN DA), and
both long and short Cav1.3 channel variants are expressed in
these cells (Olson et al., 2005), we also tested if spontaneous
pacemaking is aﬀected in these neurons. However, no diﬀerence
was observed between SN DA neurons in acute brain slices from
Cav1.3DCRDHA/HA mice and their WT littermates (Figure 11).
Discussion
We generated a novel Cav1.3 mouse model that allowed us
to speciﬁcally study the role of a C-terminal automodulatory
domain previously discovered in recombinant expression
systems (Singh et al., 2008; Tan et al., 2011) but with unknown
function on ICa in native cells and in vivo functions. By
introducing an HA-antibody tag we disrupted CTM function in
vivo and thus induced the gating behavior of short Cav1.3 splice
variants also in the long Cav1.3 isoform. Study of the mutant
channels in several tissues provided us with novel insights
into the physiological role of this modulatory mechanism. We
show that it is required for ﬁne-tuning of the activity of Cav1.3
channels not only in recombinant systems but also in their native
environment. The functional impact of the CTM varies in a
cell-type speciﬁc manner: it supports a fast, Ca2+-dependent
component of channel inactivation in IHCs but suppresses CDI
in MCCs. Although Cav1.3 LTCC currents account for only
FIGURE 11 | Spontaneous pacemaking in WT and Cav1.3DCRDHA/HA
SN DA neurons. (A) Cav1.3DCRDHA/HA (HA) and WT neurons were held
in cell-attached mode (sample traces). (B) They typically fired continuously
with no statistical differences in frequencies (WT: 2.5 ± 0.2 Hz, n = 13;
HA: 2.8 ± 0.2 Hz, n = 12; mean ± SE) and the coefficient of variation of
the inter-spike interval (ISI CV) (0.045 ± 0.009 for WT and 0.048 ± 0.010
for HA). Putative dopamine neurons in the substantia nigra pars compacta
were identified based of their position within the slice, their large size and
the presence of IH−mediated hyperpolarization upon current injection
(>100 pA). Dopamine neurons were dialyzed with biocytin. After tissue
fixation, their identity was verified by streptavidin and tyrosine hydroxylase
(TH) co-staining.
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about 25% of the total ICa in MCCs (Marcantoni et al., 2010),
interruption of CTM function caused a profound change in their
electrical activity. This was reﬂected by a more negative resting
potential, reduced Ca2+-inﬂux during spontaneous pacemaking,
less spontaneous activity and less spike frequency adaptation.
These changes could be explained by increased CDI in mutant
channels with reduced signaling to SK-channels (Vandael et al.,
2012).
Several groups have revealed important molecular details of
CaM-regulation of VGCCs including Cav1.3 and Cav1.2 LTCCs
(Christel and Lee, 2012; Ben-Johny and Yue, 2014 employing
recombinant channels expressed in mammalian cells (mainly
HEK-293). This has not only provided critical insight into CaM-
mediated CDI and Ca2+-dependent facilitation, but also into
mechanisms that adjust the strength of CaM modulation even
further. By reducing the aﬃnity for apoCaM pre-association
with the proximal C-terminus of the α1-subunit CaM regulation
becomes tunable by ambient CaM concentrations (Bazzazi et al.,
2013). The CTM studied here represents such a mechanism,
in addition to RNA editing (Huang et al., 2012). Moreover,
CaBPs which do not mediate CDI can competitively (Oz et al.,
2011; Findeisen et al., 2013) and/or allosterically aﬀect CaM
binding (Yang et al., 2014) and completely remove CDI when
overexpressed with Cav1.3. However, much less is known about
how this complex modulation aﬀects Cav1.3 channel activity in
excitable cells that diﬀer with respect to intracellular CaM and
CaBP concentrations, RNA editing, and the relative abundance
of long and short Cav1.3 splice variants. Our mouse model
allowed us to directly investigate this question. By selecting two
diﬀerent cell types, IHCs and MCCs, in which Cav1.3 current
components can be measured separate from other L- and non-
L-type currents, we demonstrate that the modulatory eﬀects of
the CTM in Cav1.3 are cell-type dependent. From the analysis
of recombinant mCav1.3L-HA channels (Figure 1) and from
previous work (Bock et al., 2011; Tan et al., 2011) we expected
that disabling CTM activity would (i) enhance ICa amplitude
(due to higher open probability, Bock et al., 2011); (ii) facilitate
channel activation atmore negative voltages and (iii) permitmore
pronounced CDI (Ben-Johny and Yue, 2014; Lieb et al., 2014).
L-type ICa in MCCs exhibit CDI (Figure 9A), and the expected
CDI increase was observed despite the fact that Cav1.3 accounts
for only about 50% of the L-type current and about 25% of total
ICa (Marcantoni et al., 2010). In contrast, IHCs are known to
display very weak, but measurable, CDI due to the abundant
expression of CaBPs. We found that this weak CDI was even
reduced in Cav1.3DCRDHA/HA IHCs. Whereas the increase in
current density is expected for channel gating unopposed by
the CTM, decreased CDI is contrary to predictions from HEK-
293 cell-expressed channels and our ﬁndings in MCCs. This
clearly demonstrates that the CTM can even promote CDI in
a speciﬁc cellular environment. An obvious explanation for this
unexpected ﬁnding is that in IHCs CaBPs and CaM compete for
modulation of CDI (Oz et al., 2011; Findeisen et al., 2013; Yang
et al., 2014). Removal of the functional CTM therefore may not
only facilitate CaM but also CaBP interaction with the channel.
We therefore hypothesize that the absence of the CTM favors
CaBP binding relative to CaM leading to the observed reduction
of CDI. Testing this hypothesis in heterologous expression
systems will be challenging due to the toxicity of CaBPs when
co-expressed with Cav1.3 (Yang et al., 2014) and the need to
demonstrate graded and quantitatively diﬀerent eﬀects of CaBPs
(in particular CaBP1 and CaBP2, the main CaBPs in IHCs,
Cui et al., 2007; Schrauwen et al., 2012) on CDI of WT and
mCav1.3L-HA or C-terminally short splice variants.
We also took advantage of the presence of an HA-antibody
tag to demonstrate that long Cav1.3 isoforms are an intrinsic
part of all Cav1.3 clusters at ribbon synapses in adult IHCs. In
both inner and outer hair cells our nested PCR data also revealed
the expression of Cav1.343S, the major short Cav1.3 α1-subunit
splice variant expressed in the brain (Bock et al., 2011; Tan et al.,
2011). The Cav1.3DCRDHA/HA mouse model will be a valuable
tool to quantify the relative abundance of long and short Cav1.3
splice variants on the protein level in IHCs and other tissues,
as reported here for brain. Western blot analysis using anti-HA
as well as N- and C-terminal anti-Cav1.3 antibodies allowed us
to conﬁrm the presence of two diﬀerent size α1-subunit species
with molecular masses diﬀering by 54 kDa. The larger band
must contain the exon 49-encoded C-terminal end that also
harbors the HA-antibody tag in Cav1.3DCRDHA/HA mice. In
WT Cav1.3 it must therefore represent the protein responsible
for “long” gating behavior in vivo. The absence of smaller
HA-tagged peptides argues against the existence of signiﬁcant
“midchannel” proteolysis of Cav1.3 (as recently postulated for
Cav1.2; Michailidis et al., 2014) and also against the presence
of stable C-terminal peptides that could serve as transcriptional
regulators. For Cav1.2 such a peptide was found to act as a
transcriptional regulator in brain (Gomez-Ospina et al., 2006)
and, non-covalently attached to cardiac Cav1.2 α1, is required
for normal regulation by cAMP-dependent protein kinase (Fu
et al., 2013). Post-translational C-terminal proteolytic cleavage
of Cav1.3 α1 has recently also been postulated for cardiac tissue
(Lu et al., 2015). However, neither our C-terminal antibody in
WTnor anti-HA antibodies in Cav1.3DCRDHA/HAmice detected
such fragments in mouse brain.
Our ﬁndings also have important implications for
understanding the pathophysiological role of Cav1.3 channels.
As outlined in the introduction, distinct changes in Cav1.3
channel gating by single missense mutations can cause human
disease. Gating changes permitting enhanced Ca2+ inward
current through Cav1.3 were not only identiﬁed as cause for
excessive aldosterone secretion in adrenal adenomas (Azizan
et al., 2013) but also as cause for PASNA, a severe human
congenital disease (Scholl et al., 2013) and as high risk de novo
mutations for autism with intellectual disability (Pinggera et al.,
2015). As our mouse model also introduces gating changes (e.g.,
steeper voltage-dependence, enhanced open probability) that
could enhance Cav1.3 mediated Ca2+-inﬂux in neurons, it is
ideally suited to address the question if dysregulation of Cav1.3
underlies neuropsychiatric phenotypes in future behavioral
studies. Interestingly, two rare genetic variants were reported
(rs41276455, rs150313433) that both neutralize the negative
charge of Asp-2117 (NCBI reference NP_000711.1), one of the
negative charges in the DEME sequence (Figure 1D) which
we have shown to be required for interaction with PCRD and
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formation of a functional CTM (Singh et al., 2008). Although
these variants have not yet been investigated for association with
disease risk, our functional data in mice suggest this possibility.
Our work emphasizes the importance of eﬀorts to identify the
in vivo functional relevance of modulatory domains in Cav1.3
LTCCs channels as shown here for the CTM.
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